Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
Study of ONC-392 in Combination with PLUVICTO in Male Patients with Prostate Cancer
Sponsor: OncoC4, Inc.
Enrolling: Male Patients Only
IRB Number: AAAU8718
U.S. Govt. ID: NCT05682443
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The main purpose of the study is to determine whether the study drug, ONC-392, together with a standard of care drug PLUVICTO (Lutetium Lu 177 Vipivotide Tetraxetan), are safe and well tolerated, and whether two drugs are effective in treating prostate cancer, in comparison with the standard of care PLUVICTO alone. ONC-392 has not yet been approved by the Food and Drug Administration (FDA). PLUVICTO is FDA-approved but is not approved to be combined with ONC-392.
Mark Stein, MD
Do You Qualify?
Are you a male and at least 18 years old? Yes No
Have you been diagnosed with prostate cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator